• Home
  •  / Sunesis Pharmaceuticals

Sunesis Pharmaceuticals

OverviewSuggest Edit

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. It develops QINPREZO (vosaroxin), an anti-cancer quinolone derivative, or AQD — a class of compounds that has not been used previously for the treatment of cancer. The Company conducts research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology.
TypePublic
Founded1987
HQSouth San Francisco, CA, USMap
Websitesunesis.com
Employee Ratings4.2More
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2018)29(-14%)
Revenue (FY, 2020)$120 K(-94%)
Share Price (Feb 2021)$18.6
Cybersecurity ratingBMore

Key People/Management at Sunesis Pharmaceuticals

Steve R. Carchedi

Steve R. Carchedi

Director
Dayton Misfeldt

Dayton Misfeldt

Director
Judith A. Fox

Judith A. Fox

Chief Scientific Officer and Executive Vice President, Research & Development
Steven B. Ketchum

Steven B. Ketchum

Director
Parvinder S. Hyare

Parvinder S. Hyare

Interim CEO and Principal Executive Officer
Nicole Onetto

Nicole Onetto

Director
Show more

Sunesis Pharmaceuticals Office Locations

Sunesis Pharmaceuticals has an office in South San Francisco
South San Francisco, CA, US (HQ)
395 Oyster Point Blvd
Show all (1)

Sunesis Pharmaceuticals Financials and Metrics

Sunesis Pharmaceuticals Revenue

Sunesis Pharmaceuticals's revenue was reported to be $120 k in FY, 2020
USD

Revenue (FY, 2020)

120.0k

Net income (FY, 2020)

(21.6m)

EBIT (FY, 2020)

(22.3m)

Market capitalization (26-Feb-2021)

96.3m

Closing stock price (26-Feb-2021)

18.6

Cash (31-Dec-2020)

20.4m

EV

76.5m
Sunesis Pharmaceuticals's current market capitalization is $96.3 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

5.0m3.8m8.0m5.7m3.1m2.5m669.0k237.0k2.1m120.0k

General and administrative expense

8.3m9.2m10.8m23.1m18.7m16.1m13.5m11.3m9.9m10.2m

R&D expense

22.6m29.2m28.9m27.7m23.7m22.9m21.5m14.6m15.4m12.3m

Operating expense total

30.9m38.4m39.7m50.8m42.4m39.0m35.1m25.9m25.4m22.4m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

1.0m1.5m265.0k2.0m2.0m2.0m2.0m2.0m854.0k854.0k854.0k683.0k640.0k610.0k610.0k669.0k237.0k120.0k

General and administrative expense

2.0m2.2m2.2m2.2m2.3m2.4m2.9m2.8m3.4m6.4m7.2m5.1m5.2m4.0m4.3m4.0m3.9m3.9m3.7m3.2m3.4m2.8m2.7m2.4m2.5m2.5m2.2m2.1m2.3m

R&D expense

6.0m6.2m6.6m8.1m6.9m7.4m7.7m7.0m7.6m7.2m6.9m4.5m6.3m5.3m6.2m6.6m5.3m6.2m4.9m6.8m4.0m3.8m3.6m3.2m3.7m3.5m3.7m4.3m2.2m

Operating expense total

7.9m8.4m8.8m10.3m9.2m9.8m10.6m9.8m11.0m13.6m14.2m9.6m11.5m9.3m10.5m10.6m9.1m10.1m8.6m9.9m7.3m6.6m6.3m5.7m6.2m6.0m5.9m6.3m4.5m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

9.3m14.9m15.1m22.2m26.9m8.1m27.0m13.7m12.8m20.4m

Prepaid Expenses

1.6m1.7m1.2m1.2m558.0k643.0k1.2m1.5m1.7m1.7m

Current Assets

45.7m72.9m40.5m44.2m47.0m43.2m32.9m15.2m36.3m22.1m

PP&E

74.0k43.0k23.0k42.0k14.0k3.0k20.0k11.0k3.0k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

7.6m11.9m5.3m11.7m41.6m12.6m6.6m21.7m50.4m26.8m20.8m18.8m20.3m16.8m23.9m9.4m5.8m11.5m11.7m7.9m21.4m17.0m20.2m24.8m9.8m19.7m20.0m17.7m26.0m

Prepaid Expenses

1.4m1.8m1.9m1.6m1.7m1.2m998.0k1.0m1.1m1.1m1.3m1.5m1.2m796.0k701.0k831.0k840.0k714.0k840.0k1.3m1.5m1.5m1.3m1.6m2.2m2.2m1.8m1.7m1.6m

Current Assets

50.3m43.5m36.7m30.9m78.2m62.2m50.6m46.5m71.8m59.7m46.0m41.3m40.7m31.3m40.7m34.0m25.1m35.9m23.5m13.7m26.9m21.9m21.5m26.4m19.8m40.5m30.7m24.9m27.6m

PP&E

94.0k82.0k66.0k58.0k50.0k36.0k31.0k27.0k41.0k35.0k53.0k31.0k19.0k17.0k11.0k8.0k6.0k1.0k25.0k22.0k18.0k16.0k14.0k9.0k7.0k5.0k1.0k
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(20.1m)(44.0m)(34.6m)(43.0m)(36.7m)(38.0m)(35.5m)(26.6m)(23.3m)(21.6m)

Depreciation and Amortization

56.0k31.0k20.0k29.0k27.0k11.0k9.0k9.0k(70.0k)(41.0k)

Accounts Payable

242.0k(580.0k)875.0k2.2m(724.0k)(582.0k)(174.0k)(304.0k)(602.0k)(312.0k)

Cash From Operating Activities

(22.8m)(10.6m)(37.4m)(43.2m)(38.7m)(37.0m)(36.1m)(24.4m)(22.2m)(21.4m)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(6.4m)(11.4m)(13.9m)(22.5m)(39.9m)(11.6m)(19.8m)(27.4m)(14.6m)(26.4m)(41.7m)(9.1m)(18.1m)(25.1m)(10.1m)(20.5m)(29.5m)(9.8m)(18.7m)(28.8m)(7.3m)(14.1m)(20.6m)(5.9m)(12.1m)(18.0m)(5.8m)(12.2m)(16.8m)

Depreciation and Amortization

38.0k47.0k8.0k16.0k24.0k7.0k12.0k16.0k5.0k11.0k18.0k11.0k22.0k24.0k3.0k6.0k8.0k2.0k4.0k7.0k2.0k4.0k6.0k2.0k4.0k6.0k(37.0k)(41.0k)(41.0k)

Accounts Payable

(87.0k)(89.0k)211.0k(265.0k)529.0k1.4m2.0m1.4m58.0k(440.0k)(181.0k)(1.1m)(895.0k)(1.4m)128.0k306.0k73.0k776.0k406.0k(330.0k)(659.0k)(144.0k)(420.0k)(532.0k)(701.0k)(623.0k)71.0k(339.0k)(641.0k)

Cash From Operating Activities

(8.9m)(15.6m)(9.3m)(15.1m)(1.4m)(9.5m)(19.0m)(27.7m)(11.4m)(21.6m)(34.2m)(11.6m)(19.8m)(29.5m)(10.7m)(20.1m)(29.0m)(9.7m)(20.5m)(30.8m)(6.5m)(12.4m)(17.9m)(6.1m)(13.0m)(18.4m)(5.7m)(11.5m)(15.8m)
show all
USDQ2, 2011

Financial Leverage

1.3 x
Show all financial metrics

Sunesis Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

B

83/100

Learn more about our premium products
SecurityScorecard logo

Sunesis Pharmaceuticals Online and Social Media Presence

Sunesis Pharmaceuticals's Trends

Embed Graph

Sunesis Pharmaceuticals News and Updates

December 01, 2020

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Sunesis Pharmaceuticals, Inc. Merger

WILMINGTON, Del., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Sunesis Pharmaceuticals, Inc. (“Sunesis”) (NASDAQ CM: SNSS) regarding possible breaches of fiduciary duties and other violations of law related to Sunesis’ agreement to merge with Vira…
November 30, 2020

Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement

Merger to create Nasdaq-listed company focused on developing Viracta’s precision oncology pipeline targeting virus-associated malignancies
October 12, 2020

Sunesis Pharmaceuticals Announces Presentation of SNS-510 Preclinical Data at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a poster presentation at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held October 24-25, 2020 in a virtual format.
August 11, 2020

Thinking about buying stock in Delta Air Lines, Eyenovia Inc, Sunesis Pharmaceuticals, Inovio Pharmaceuticals, or Moderna Inc?

NEW YORK, Aug. 11, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DAL, EYEN, SNSS, INO, and MRNA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
July 27, 2020

Thinking about buying stock in Vivint Solar, Actinium Pharmaceuticals, Delta Air Lines, Sunesis Pharmaceuticals, or Novan Inc?

NEW YORK, July 27, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VSLR, ATNM, DAL, SNSS, and NOVN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
June 23, 2020

Thinking about buying stock in Sunesis Pharmaceuticals, TOP Ships, Lilis Energy, Seanergy Maritime Holdings, or Plug Power?

NEW YORK, June 23, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNSS, TOPS, LLEX, SHIP, and PLUG. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
Show more

Sunesis Pharmaceuticals Blogs

June 11, 2021

VP/Senior Director, Investor Relations & Corporate Communications

Viracta Therapeutics is public biotechnology company committed to advancing new medicines to benefit patients with viral-associated cancers and other serious diseases. Viracta’s proprietary platform is a highly targeted combination therapy approach for virus-associated malignancies. Our initial focu…
May 18, 2021

Regulatory Affairs Sr. Associate

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta’s proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive l…
April 05, 2021

Senior Director, Formulation Development & Manufacturing

Position Title: Senior Director, Formulation Development & ManufacturingFunctional Area: CMC operation ABOUT VIRACTA THERAPEUTICS: Viracta Therapeutics is a rapid growing, public biotechnology company committed to advancing new medicines to benefit patients with viral-associated cancers and othe…
March 04, 2021

Barry J. Simon, M.D.

Barry J. Simon, M.D., is a healthcare executive with more than 30 years of experience spanning the public and private sectors. He previously served on Viracta’s board from July 2017 to November 2020 and has been serving as Director and CCAO of Immunity Bio, Inc. since March 2021.  Prior to this, he …
February 25, 2021

Drug Safety Manager

Functional Area: Safety/Clinical OperationsJob Type: Full Time, office based (Cardiff, CA); Remote may be consideredRequired education: BS or advanced degree in physical or life sciences preferredArea(s) of expertise desired: 3+ years of relevant experience in pharmaceutical or biotechnology industr…
February 24, 2021

Manager, SEC Reporting and SOX Compliance

Position Title: Manager, SEC Reporting and SOX ComplianceFunctional Area: Finance and AccountingJob Type: Full TimeRequired education: BS degree in accountingArea(s) of expertise desired: Public company experience, 4-6 years of relevant experience ABOUT VIRACTA THERAPEUTICS: Viracta Therapeutics is …
Show more

 Sunesis Pharmaceuticals Frequently Asked Questions

  • When was Sunesis Pharmaceuticals founded?

    Sunesis Pharmaceuticals was founded in 1987.

  • Who are Sunesis Pharmaceuticals key executives?

    Sunesis Pharmaceuticals's key executives are Steve R. Carchedi, Dayton Misfeldt and Judith A. Fox.

  • How many employees does Sunesis Pharmaceuticals have?

    Sunesis Pharmaceuticals has 29 employees.

  • What is Sunesis Pharmaceuticals revenue?

    Latest Sunesis Pharmaceuticals annual revenue is $120 k.

  • What is Sunesis Pharmaceuticals revenue per employee?

    Latest Sunesis Pharmaceuticals revenue per employee is $4.1 k.

  • Who are Sunesis Pharmaceuticals competitors?

    Competitors of Sunesis Pharmaceuticals include Captor Therapeutics, OBI Pharma and Vascular Biogenics.

  • Where is Sunesis Pharmaceuticals headquarters?

    Sunesis Pharmaceuticals headquarters is located at 395 Oyster Point Blvd, South San Francisco.

  • Where are Sunesis Pharmaceuticals offices?

    Sunesis Pharmaceuticals has an office in South San Francisco.

  • How many offices does Sunesis Pharmaceuticals have?

    Sunesis Pharmaceuticals has 1 office.